This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1999;4(2):138-9.

The molecular perspective: p53 tumor suppressor

Affiliations

PMID: 10337384

Free article

The molecular perspective: p53 tumor suppressor

D S Goodsell. Oncologist. 1999.

Free article

. 1999;4(2):138-9.

Author

Affiliation

¹ Scripps Research Institute, Department of Molecular Biology, La Jolla, California 92037, USA. goodsell@scripps.edu

PMID: 10337384

No abstract available

PubMed Disclaimer

Similar articles

[TP53 tumor suppressor gene: 20 years (and ten thousand mutations) later].
Hainaut P. Hainaut P. Bull Cancer. 2000 Jan;87(1):11-8. Bull Cancer. 2000. PMID: 10673626 French. No abstract available.
[The tumor suppressor gene p53 (part one). Structure, function and mechanisms of inactivation].
Martin A. Martin A. Ann Pathol. 1995;15(3):178-83. Ann Pathol. 1995. PMID: 7639853 Review. French. No abstract available.
The p53 tumour suppressor gene and product.
Levine AJ. Levine AJ. Cancer Surv. 1992;12:59-79. Cancer Surv. 1992. PMID: 1638548 Review. No abstract available.
p53, the cellular gatekeeper for growth and division.
Levine AJ. Levine AJ. Cell. 1997 Feb 7;88(3):323-31. doi: 10.1016/s0092-8674(00)81871-1. Cell. 1997. PMID: 9039259 Review. No abstract available.
[Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA, Cerbón MA. Mendoza-Rodríguez CA, et al. Rev Invest Clin. 2001 May-Jun;53(3):266-73. Rev Invest Clin. 2001. PMID: 11496714 Review. Spanish.

See all similar articles

Cited by

Association of the p53 or GSTM1 polymorphism with the risk of nasopharyngeal carcinoma: A meta-analysis.
Wu M, Huang S, Liu D, Peng M, Yang F, Wang X. Wu M, et al. Mol Clin Oncol. 2016 Feb;4(2):221-228. doi: 10.3892/mco.2015.700. Epub 2015 Dec 8. Mol Clin Oncol. 2016. PMID: 26893866 Free PMC article.
The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.
Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF, Mokbel K. Al Sarakbi W, et al. BMC Cancer. 2009 Aug 21;9:290. doi: 10.1186/1471-2407-9-290. BMC Cancer. 2009. PMID: 19698110 Free PMC article.
Association between the P53 codon 72 polymorphism and nasopharyngeal cancer risk.
Cai K, Wang Y, Zhao X, Bao X. Cai K, et al. Tumour Biol. 2014 Mar;35(3):1891-7. doi: 10.1007/s13277-013-1254-5. Epub 2013 Oct 11. Tumour Biol. 2014. PMID: 24114013
Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD, English DP, Roque DM, Santin AD. Black JD, et al. Womens Health (Lond). 2014 Jan;10(1):45-57. doi: 10.2217/whe.13.72. Womens Health (Lond). 2014. PMID: 24328598 Free PMC article. Review.
Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity.
Kamath VP, Torres-Roca JF, Eschrich SA. Kamath VP, et al. Int J Genomics. 2017;2017:6576840. doi: 10.1155/2017/6576840. Epub 2017 Feb 8. Int J Genomics. 2017. PMID: 28280724 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Wiley
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal